{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:27:44Z","timestamp":1793158064444,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"2024 Wuxi City Specialized Traditional Chinese Medicine Technology Development Project","award":["ZYYB202402"],"award-info":[{"award-number":["ZYYB202402"]}]},{"name":"Jiangyin Municipal Health Commission Scientific Research Project","award":["Z202202"],"award-info":[{"award-number":["Z202202"]}]},{"name":"Chinese Association of Chinese Medicine Research Project on Clinical Studies of National\/Provincial Standard-Based Traditional Chinese Medicine Formula Granules","award":["ZA_CACM_2024003"],"award-info":[{"award-number":["ZA_CACM_2024003"]}]},{"name":"Jiangsu Association of Chinese Medicine Scientific Research Project","award":["PDJH2024028"],"award-info":[{"award-number":["PDJH2024028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The host microbiota and hepatic drug-metabolizing enzymes are important mediators of the metabolism and biological effects of herbal components. Through bidirectional interactions, herbal medicines can also reshape the host microbial community. The clinical efficacy of Wendan Decoction (WDD) in treating metabolic dysfunction-associated fatty liver disease (MAFLD) has been well established. However, its interactions with the host microbiota through the gut-liver axis remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to investigate the mechanism by which WDD modulates host microbial activity through the gut-liver axis to ameliorate MAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      MAFLD models were established by high-fat diet (HFD) feeding and subsequently treated with WDD,\n                      <jats:italic>Parasutterella excrementihominis<\/jats:italic>\n                      (\n                      <jats:italic>P. excrementihominis<\/jats:italic>\n                      ), or 7\u03b1-OH-T. The ABX group underwent antibiotic-mediated microbiota depletion before treatment. Multi-omics analyses were used to characterize the dynamic trajectories of microbiota-derived metabolites. These analyses included targeted bile acid (BA) profiling of serum, 16S rRNA gene sequencing and untargeted metabolomics of cecal contents, and proteomics and untargeted metabolomics of liver tissue. Hematoxylin and eosin, Oil Red O, and Alcian blue-periodic acid-Schiff staining were used to assess pathological changes in the liver and intestinal tissues during MAFLD. ELISA, Western blotting, and other assays were performed to quantify markers of inflammation and lipid metabolism. Following UPLC\/UV detection of 7\u03b1-OH-T in portal vein serum, molecular docking and molecular dynamics simulations, together with cellular thermal shift assays (CETSA) and microscale thermophoresis (MST), were used to validate FXR as a target of 7\u03b1-OH-T.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      WDD alleviated hepatic steatosis, intestinal inflammation, and barrier dysfunction in MAFLD, but these effects depended on the integrity of the host microbiota. 16S rRNA gene sequencing showed that WDD promoted the growth of beneficial bacteria, including\n                      <jats:italic>Bacteroides<\/jats:italic>\n                      and\n                      <jats:italic>Parasutterella<\/jats:italic>\n                      . Combined analysis of targeted serum BA metabolomics and untargeted metabolomics of cecal contents indicated that WDD-mediated modulation of the host microbiota reduced the total serum BA load, increased alternative-pathway metabolites, including CDCA and TCDCA, in the liver and intestine, and decreased toxic secondary BAs, including DCA and LCA. Steroid and fatty acid metabolites, such as 7\u03b1-OH-T, were also increased.\n                      <jats:italic>Pearson<\/jats:italic>\n                      correlation analysis and\n                      <jats:italic>P. excrementihominis<\/jats:italic>\n                      transplantation experiments suggested that the increase in 7\u03b1-OH-T was closely associated with\n                      <jats:italic>P. excrementihominis<\/jats:italic>\n                      . Untargeted liver metabolomics and serological analyses confirmed that gut-derived 7\u03b1-OH-T entered the liver through the portal vein and acted on hepatic targets via the gut-liver axis. In animal experiments involving exogenous 7\u03b1-OH-T supplementation and in MAFLD THLE-2 cell models treated with 7\u03b1-OH-T, 7\u03b1-OH-T ameliorated hepatic lipid accumulation and promoted lipid utilization in THLE-2 cells. A series of interaction assays, including CETSA and MST, identified FXR as a target of 7\u03b1-OH-T. Furthermore, 7\u03b1-OH-T markedly activated the FXR\/PPAR\u03b1\/CYP4A12A axis and served as a key messenger through which WDD-mediated regulation of\n                      <jats:italic>Parasutterella<\/jats:italic>\n                      alleviated MAFLD via the gut-liver axis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      WDD increased the abundance of\n                      <jats:italic>P. excrementihominis<\/jats:italic>\n                      and the level of the potentially associated metabolite 7\u03b1-OH-T. Through the portal circulation, 7\u03b1-OH-T promoted gut-liver crosstalk and targeted the FXR\/PPAR\u03b1\/CYP4A12A axis, thereby ameliorating MAFLD.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-026-01474-1","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:13:16Z","timestamp":1784527996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Wendan decoction modulates Parasutterella to influence fatty acid metabolism in MAFLD via the FXR\/PPAR\u03b1\/CYP4A12A axis"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6403-6051","authenticated-orcid":false,"given":"Yiheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianle","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihua","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibing","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"8","key":"1474_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0330504","volume":"20","author":"Y Mao","year":"1990","unstructured":"Mao Y, Du J, Li B, et al. Global burden of NAFLD 1990-2021 and projections to 2035: results from the Global Burden of Disease study 2021. PLoS ONE. 1990;20(8):e0330504.","journal-title":"PLoS ONE"},{"issue":"13","key":"1474_CR2","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.cgh.2025.02.006","volume":"23","author":"GJK Ho","year":"2025","unstructured":"Ho GJK, Tan FXN, Sasikumar NA, et al. High global prevalence of steatotic liver disease and associated subtypes: a meta-analysis. Clin Gastroenterol Hepatol. 2025;23(13):2423-32.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"1474_CR3","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2016","unstructured":"Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2016;69(4):896\u2013904.","journal-title":"J Hepatol"},{"issue":"6737","key":"1474_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/science.adp4120","volume":"387","author":"K Ding","year":"2025","unstructured":"Ding K, Zhang Z, Han Z, et al. Liver ALKBH5 regulates glucose and lipid homeostasis independently through GCGR and mTORC1 signaling. Science. 2025;387(6737):eadp4120.","journal-title":"Science"},{"issue":"10","key":"1474_CR5","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/j.cmet.2024.07.014","volume":"36","author":"B Zhou","year":"2024","unstructured":"Zhou B, Luo Y, Bi H, et al. Amelioration of nonalcoholic fatty liver disease by inhibiting the deubiquitylating enzyme RPN11. Cell Metab. 2024;36(10):2228-44.e7.","journal-title":"Cell Metab"},{"key":"1474_CR6","doi-asserted-by":"publisher","first-page":"1597995","DOI":"10.3389\/fmicb.2025.1597995","volume":"16","author":"W Yang","year":"2025","unstructured":"Yang W, Jin Q, Xiao D, et al. Interaction mechanism and intervention strategy between metabolic dysfunction-associated steatotic liver disease and intestinal microbiota. Front Microbiol. 2025;16:1597995.","journal-title":"Front Microbiol"},{"key":"1474_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2026.117897","volume":"249","author":"YQ Guo","year":"2026","unstructured":"Guo YQ, Jia CX, Zhu TL, et al. Mechanism and interventions of the bile acid-gut-liver axis imbalance in the progression of non-alcoholic fatty liver disease. Biochem Pharmacol. 2026;249:117897.","journal-title":"Biochem Pharmacol"},{"key":"1474_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.157028","volume":"145","author":"Y Tian","year":"2025","unstructured":"Tian Y, Meng J, Zhang D, et al. Wendan decoction exerts therapeutic effects on insomnia by regulating gut microbiota and tryptophan metabolism. Phytomedicine. 2025;145:157028.","journal-title":"Phytomedicine"},{"key":"1474_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.157119","volume":"146","author":"Z Su","year":"2025","unstructured":"Su Z, Li Y, Zhou Z, et al. Huanglian Wendan decoction alleviates metabolic syndrome by reprogramming macrophage polarization: evidence from multi-omics integration. Phytomedicine. 2025;146:157119.","journal-title":"Phytomedicine"},{"issue":"8","key":"1474_CR10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1023\/B:PHAM.0000036921.87928.72","volume":"21","author":"L Letendre","year":"2004","unstructured":"Letendre L, Scott M, Dobson G, et al. Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. Pharm Res. 2004;21(8):1457\u201362.","journal-title":"Pharm Res"},{"issue":"11","key":"1474_CR11","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.chom.2025.09.009","volume":"33","author":"R DE Oliveira Formiga","year":"2025","unstructured":"DE Oliveira Formiga R, Li Q, Zhao Y, et al. Immunometabolic reprogramming of macrophages by gut microbiota-derived cadaverine controls colon inflammation. Cell Host Microbe. 2025;33(11):1855-72.e10.","journal-title":"Cell Host Microbe"},{"issue":"12","key":"1474_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412865","volume":"12","author":"J Liu","year":"2025","unstructured":"Liu J, Liu Y, Huang C, et al. Quercetin-driven akkermansia muciniphila alleviates obesity by modulating bile acid metabolism via an ILA\/m(6)A\/CYP8B1 signaling. Adv Sci (Weinh). 2025;12(12):e2412865.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"1474_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101883","volume":"6","author":"X Li","year":"2025","unstructured":"Li X, Zheng S, Xu H, et al. The direct and indirect inhibition of proinflammatory adipose tissue macrophages by acarbose in diet-induced obesity. Cell Rep Med. 2025;6(1):101883.","journal-title":"Cell Rep Med"},{"issue":"2","key":"1474_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3892\/br.2015.557","volume":"4","author":"Z Hu","year":"2016","unstructured":"Hu Z, Ma R, Gong J. Investigation of testosterone-mediated non-transcriptional inhibition of Ca2+ in vascular smooth muscle cells. Biomed Rep. 2016;4(2):197\u2013202.","journal-title":"Biomed Rep"},{"issue":"5","key":"1474_CR15","first-page":"731","volume":"9","author":"TO Kolaric","year":"2021","unstructured":"Kolaric TO, Nincevic V, Kuna L, et al. Drug-induced fatty liver disease: pathogenesis and treatment. J Clin Transl Hepatol. 2021;9(5):731\u20137.","journal-title":"J Clin Transl Hepatol"},{"issue":"7","key":"1474_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.trecan.2022.02.009","volume":"8","author":"MAD Silveira","year":"2022","unstructured":"Silveira MAD, Bilodeau S, Greten TF, et al. The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis. Trends Cancer. 2022;8(7):583\u201397.","journal-title":"Trends Cancer"},{"issue":"1","key":"1474_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07478-z","volume":"24","author":"SM Won","year":"2025","unstructured":"Won SM, Joung H, Park IG, et al. The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial. J Transl Med. 2025;24(1):61.","journal-title":"J Transl Med"},{"issue":"3","key":"1474_CR18","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1007\/s12602-025-10761-6","volume":"18","author":"SJ Yoon","year":"2025","unstructured":"Yoon SJ, Choi J, Won SM, et al. Probiotic-derived strain-specific metabolites ameliorate metabolic dysfunction-associated steatotic liver disease through modulation of the gut-liver axis. Probiotics Antimicrob Proteins. 2025;18(3):4353\u201366.","journal-title":"Probiotics Antimicrob Proteins"},{"key":"1474_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jare.2024.01.019","volume":"67","author":"J Li","year":"2025","unstructured":"Li J, Guo C, Liu Y, et al. Chronic arsenic exposure-provoked biotoxicity involved in liver-microbiota-gut axis disruption in chickens based on multi-omics technologies. J Adv Res. 2025;67:373\u201386.","journal-title":"J Adv Res"},{"issue":"6","key":"1474_CR20","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/s41396-019-0364-5","volume":"13","author":"T Ju","year":"2019","unstructured":"Ju T, Kong JY, Stothard P, et al. Defining the role of Parasutterella, a previously uncharacterized member of the core gut microbiota. ISME J. 2019;13(6):1520\u201334.","journal-title":"ISME J"},{"issue":"1","key":"1474_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40795-020-00398-9","volume":"6","author":"JR Bush","year":"2020","unstructured":"Bush JR, Alfa MJ. Increasing levels of Parasutterella in the gut microbiome correlate with improving low-density lipoprotein levels in healthy adults consuming resistant potato starch during a randomised trial [J]. BMC Nutr. 2020;6(1):72.","journal-title":"BMC Nutr"},{"issue":"9","key":"1474_CR22","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1210\/en.2005-1485","volume":"147","author":"S Wang","year":"2006","unstructured":"Wang S, Lai K, Moy FJ, et al. The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. Endocrinology. 2006;147(9):4025\u201333.","journal-title":"Endocrinology"},{"key":"1474_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13061422","author":"A Liu","year":"2025","unstructured":"Liu A, Huang M, Xi Y, et al. Orchestration of gut-liver-associated transcription factors in MAFLD: from cross-organ interactions to therapeutic innovation. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13061422.","journal-title":"Biomedicines"},{"key":"1474_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.05.028","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ma T, Lu X, et al. Mechanical mechanics-reclaiming a new battlefield for chronic liver disease. J Adv Res. 2025. https:\/\/doi.org\/10.1016\/j.jare.2025.05.028.","journal-title":"J Adv Res"},{"key":"1474_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1569915","volume":"16","author":"Q Wu","year":"2025","unstructured":"Wu Q, Yang Y, Lin S, et al. The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC. Front Immunol. 2025;16:1569915.","journal-title":"Front Immunol"},{"key":"1474_CR26","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.omtn.2021.10.022","volume":"26","author":"X Luo","year":"2021","unstructured":"Luo X, Xu ZX, Wu JC, et al. Hepatocyte-derived exosomal miR-27a activates hepatic stellate cells through the inhibition of PINK1-mediated mitophagy in MAFLD. Mol Ther Nucleic Acids. 2021;26:1241\u201354.","journal-title":"Mol Ther Nucleic Acids"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01474-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-026-01474-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01474-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:02:40Z","timestamp":1784574160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-026-01474-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1474"],"URL":"https:\/\/doi.org\/10.1186\/s13020-026-01474-1","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal care and experimental procedures were performed in accordance with the guidelines of the Animal Ethics Committee of the Nanjing University of Chinese Medicine.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"200"}}